Drugs / Melan-A vaccine
last change Nov 2011 re-read 2 minutes ago

Melan-A vaccine

Developed for
cutaneous melanoma
Investigated by
Prof. Serge Leyvraz

Trials 1 · a red edge is where a trial was stopped

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00324623 Sep 2005 → Nov 2011 cutaneous melanoma Prof. Serge Leyvraz Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Melan-A vaccine “Patients also receive vaccination comprising Melan-A vaccine emulsified in incomplete Freund's adjuvant (IFA) subcutaneously (SC) once every 3 weeks beginning on day 0.” NCT00324623
Route Subcutaneous “Melan-A vaccine emulsified in incomplete Freund's adjuvant (IFA) subcutaneously (SC)” NCT00324623